Axion BioSystems’ Post

Want to know more about single-cell sequencing of organoids? Read our app note!

#Organoids are a powerful new cell model, but there are often 2 major challenges: 1. Organoids can be difficult to produce consistently. 2. Organoids can be difficult to study in a non-destructive manner. In this 8-minute video I discuss standardizing organoid production and analysis for functional neural disease modeling. You can watch the full video here: https://lnkd.in/es55BV55 #Neuroscience #StemCells #Organonachip #Biotech #AxionBio Axion BioSystems, NETRI

Our panel of models allow for more accurate prediction of human responses, reduce the risk of late-stage failures and provide a thorough understanding of drug mechanisms. ✔️ Ion channel expressing cell lines for central and peripheral nervous system targets ✔️Primary neuronal cultures, including dissociated cortical, trigeminal or dorsal root ganglion (DRG) neurons from rodents (Figure 1) ✔️CNS drug discovery to understand the effects of test compounds on brain slice tissue ✔️Human iPSC-derived neurons https://hubs.la/Q02PYN5h0 #drugdiscovery #CRO #CNS #Neuroscience #ionchannels

Molecular Mechanism of Alpha-Synuclein in Parkinson's Disease Alpha-synuclein is central to the pathology of Parkinson's disease. Here’s a breakdown of its molecular mechanism:Misfolding: Normally, alpha-synuclein helps with neurotransmitter release. However, it can misfold and form toxic aggregates. Aggregation: Misfolded alpha-synuclein clumps together, forming Lewy bodies that disrupt cellular functions. Mitochondrial Dysfunction: These aggregates can impair mitochondrial function, leading to energy deficits and increased oxidative stress in neurons. Neuroinflammation: The presence of Lewy bodies triggers an inflammatory response, further damaging surrounding neurons. Neuronal Death: Over time, the cumulative effects lead to the degeneration of dopamine-producing neurons, causing the hallmark symptoms of Parkinson's. Understanding this mechanism is crucial for developing targeted therapies. Stay aware and support Parkinson’s research! Parkinson's Ireland #ParkinsonsDisease #AlphaSynuclein #Neuroscience

In a study published in Analytical and Bioanalytical Chemistry (2024), researchers explored the metabolic changes in the brain following traumatic brain injury (TBI) using an innovative mass spectrometry imaging (MSI) technique, specifically AP-MALDI MSI. The study, conducted by Siciliano et al., focused on mapping the distribution of small metabolites in the brains of mice 21 days post-TBI. They identified significant changes in metabolites such as alanine, lysine, histidine, and inosine, particularly in the ipsilateral thalamus, the brain region most impacted by the injury. The findings highlight the potential of high-resolution MSI to reveal region-specific metabolic alterations that could influence the progression and outcomes of TBI. This research underscores the value of MSI in understanding the complex biochemical landscape of brain injuries, which may eventually guide therapeutic strategies. #TraumaticBrainInjury #MassSpectrometry #Neuroscience #Metabolomics #TBIResearch

Exciting research news from our team! 🧠 My colleague is presenting our work on a novel, oral, CNS-penetrant CSF1R inhibitor at the Society for Neuroscience 2024 in Chicago. This research could pave the way for new therapies for patients suffering from neuroinflammatory diseases. 🔬 Poster Title: "Targeting Chronically Active Microglia: CSF1R Inhibition for Treating Multiple Sclerosis" 📅 Date: Sunday, October 6, 2024 ⏰ Time: 1:00 - 5:00 p.m. CT 📍 Session: Multiple Sclerosis, Leukodystrophies, and Oligodendrocyte Myelination 🔢 Poster#: PSTR105.18 If you're attending #SfN2024, don't miss this promising research that could bring hope to those affected by neuroinflammatory conditions. #Neuroscience #MultipleSclerosis #ALS #Neurodegeneration #ResearchInnovation #SfN2024 #NeuroscienceResearch

💡 Parkinson’s & Alzheimer’s link to toxic protein aggregates, driving the need for new treatments. 🐝 Inspired by wasp venom, Dr. Yuri Alves de Oliveira Só et al's peptides Fraternine-10 and Octovespin show promise in disrupting and preventing the formation of fibrils associated with these diseases. ⚙️ Molecular dynamics simulations reveal their therapeutic potential. 🤔 How can we further leverage nature-inspired molecules like these to combat #neurodegenerative diseases? Universidade de Brasília #Neuroscience #Bioinspiration 🧩

🔬 Biocytogen’s Advanced Neurobehavioral Testing Platform 🔬 Genetic rodent models are crucial for offering insights into the behavior, pathology, and potential CNS therapies for neurobehavioral disorders. At Biocytogen, we provide a comprehensive portfolio of genetically humanized mouse models and advanced CNS disease models, along with a cutting-edge neurobehavioral testing platform to evaluate phenotypes across key functions, including anxiety, cognition, learning, memory, movement, perception, and more. Innovate the future of neurobehavioral research with us!🚀 #NeuroScience #Biocytogen #CNSResearch #NeurobehavioralTesting #Pharmacology #BiotechInnovations #ResearchAdvances #GeneticModels #InnovationInScience

Cellular models of neurodegenerative diseases play an integral role in preclinical drug discovery, and safety studies. Patient iPSC-derived dopamine neurons along with Multi-Electrode Array (MEA) assay provide a useful platform to investigate functional phenotypes both at the individual neuron and network levels. CRL now offers testing of small molecules aimed at reversing pathophysiology linked with cellular models of neurodegenerative diseases. For more details contact our client service https://lnkd.in/eGbNJsNC or connect with our specialists Amit Kumar Chouhan, PhD, Eddie Burns and Dario Magnani #CharlesRiver #drugdevelopment #Pharmacology #neuroscience #drugdiscovery #neurology #neurodegeneration #parkinsonsdisease Follow us at Discovery | Charles River

On World Alzheimer’s day we celebrate the advances in biology and drug discovery that are delivering new treatments for Alzheimer’s and new hope for people with neurodegenerative disorders. At NRG we are energizing drug discovery in neurodegenerative diseases and advancing a pipeline of first-in-class brain-penetrant, oral small molecule drug candidates as potential disease modifying treatments based on breakthrough science in the field of mitochondrial biology. The goal for our inhibitors of the mitochondrial permeability transition pore (#mPTP) is to restore mitochondrial function and thereby slow or halt the progression of #ALS (also known as motor neurone disease #MND), Parkinson’s and eventually other neurodegenerative diseases such as Alzheimer’s. #DrugDiscovery #neuroscience #NeurodegenerativeDisorders #Innovation #WorldAlzheimer’sDay